Investment |
9 Months Ended |
---|---|
Jun. 30, 2020 | |
Investment | |
Investment |
9. Investment The Company owns common and preferred shares of DepYmed, Inc. (“DepYmed”), which in aggregate represents approximately 14.84% ownership of DepYmed. In addition, the Company is entitled to hold two of the six seats on DepYmed’s board of directors. The Company accounts for its investment in DepYmed common shares using the equity method of accounting and records its proportionate share of DepYmed’s net income and losses in the accompanying condensed consolidated statements of operations. Equity in losses for the three and nine months ended June 30, 2020 was approximately $0.1 million and $0.2 million, respectively. The Company accounts for its investment in preferred shares of DepYmed at cost, less any impairment, as the Company determined the preferred stock did not have a readily determinable fair value. As of June 30, 2020 and September 30, 2019, the carrying amount of the Company’s aggregate investment in DepYmed was $0.4 million and $0.6 million, respectively. |
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|